Learning to Breathe: Optimizing Management of COPD Based on Device Selection

Kyle Copeland, PharmD
Published Online: Wednesday, April 17, 2013
Follow Pharmacy_Times:
This activity is supported by an educational grant from Mylan Specialty, LP.

Learning to Breathe: Optimizing Management of COPD Based on Device Selection

Kyle Copeland, PharmD
Clinical Pharmacist Specialist
Parkwest Medical Center
Knoxville, Tennessee



Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty
Kyle Copeland, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA; and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.


Educational Objectives

Upon completion of the educational activity, the participant should be able to:
  1. Review current treatment recommendations for chronic obstructive pulmonary disease (COPD).
  2. Examine currently available medication devices (eg, metered-dose inhalers, dry powder inhalers, nebulizers) in COPD and use of patient-specific factors in device selection.
  3. Explore the pharmacist's role in device section and assessing proper device use.
  4. Apply the COPD device algorithm to determine the best treatment modality for a given patient.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: April 10, 2013
Expiration date: April 10, 2015
Estimated time to complete activity: 2 hours
Fee: Free

Click here to view this lesson.


Related Articles
Novartis announced that it has submitted New Drug Applications to the FDA for QVA149 and NVA237, investigational drugs for the long-term maintenance treatment of chronic obstructive pulmonary disease, following positive results from phase 3 trials of the drugs.
Rhinovirus infection tends to aggravate other conditions in the elderly.
Tiotropium, a once-daily inhaled long-acting anticholinergic bronchodilator, provides airflow improvement for at least 24 hours in chronic obstructive pulmonary disease patients. Its use has been linked to fewer exacerbations, less dyspnea, and improved quality of life.
Patients with bronchial asthma or chronic obstructive pulmonary disease fare best with metered dose inhalers that have spacer devices.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$